The role of systemic therapy in the management of sinonasal cancer: A critical review

Paolo Bossi, Nabil F. Saba, Jan B. Vermorken, Primoz Strojan, Laura Pala, Remco De Bree, Juan Pablo Rodrigo, Fernando Lopez, Ehab Y. Hanna, Missak Haigentz, Robert P. Takes, Piet J. Slootweg, Carl E. Silver, Alessandra Rinaldo, Alfio Ferlito

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Purpose: Due to the rarity and the variety of histological types of sinonasal cancers, there is a paucity of data regarding strategy for their optimal treatment. Generally, outcomes of advanced and higher grade tumors remain unsatisfactory, despite the employment of sophisticated surgical approaches, technical advances in radiation techniques and the use of heavy ion particles. In this context, we critically evaluated the role of systemic therapy as part of a multidisciplinary approach to locally advanced disease. Results: Induction chemotherapy has shown encouraging activity and could have a role in the multimodal treatment of patients with advanced sinonasal tumors. For epithelial tumors, the most frequently employed chemotherapy is cisplatin, in combination with either 5-fluorouracil, taxane, ifosfamide, or vincristine. Only limited experiences with concurrent chemoradiation exist with sinonasal cancer. The role of systemic treatment for each histological type (intestinal-type adenocarcinoma, sinonasal undifferentiated carcinoma, sinonasal neuroendocrine carcinoma, olfactory neuroblastoma, sinonasal primary mucosal melanoma, sarcoma) is discussed. Conclusions: The treatment of SNC requires a multimodal approach. Employment of systemic therapy for locally advanced disease could result in better outcomes, and optimize the therapeutic armamentarium. Further studies are needed to precisely define the role of systemic therapy and identify the optimal sequencing for its administration in relation to local therapies.

Original languageEnglish (US)
Pages (from-to)836-843
Number of pages8
JournalCancer Treatment Reviews
Volume41
Issue number10
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Olfactory Esthesioneuroblastoma
Neuroendocrine Carcinoma
Heavy Ions
Combined Modality Therapy
Ifosfamide
Induction Chemotherapy
Vincristine
Fluorouracil
Sarcoma
Cisplatin
Melanoma
Adenocarcinoma
Radiation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Bossi, P., Saba, N. F., Vermorken, J. B., Strojan, P., Pala, L., De Bree, R., ... Ferlito, A. (2015). The role of systemic therapy in the management of sinonasal cancer: A critical review. Cancer Treatment Reviews, 41(10), 836-843. https://doi.org/10.1016/j.ctrv.2015.07.004
Bossi, Paolo ; Saba, Nabil F. ; Vermorken, Jan B. ; Strojan, Primoz ; Pala, Laura ; De Bree, Remco ; Rodrigo, Juan Pablo ; Lopez, Fernando ; Hanna, Ehab Y. ; Haigentz, Missak ; Takes, Robert P. ; Slootweg, Piet J. ; Silver, Carl E. ; Rinaldo, Alessandra ; Ferlito, Alfio. / The role of systemic therapy in the management of sinonasal cancer : A critical review. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 10. pp. 836-843.
@article{623c80f08ba94ea492920858db6f2620,
title = "The role of systemic therapy in the management of sinonasal cancer: A critical review",
abstract = "Purpose: Due to the rarity and the variety of histological types of sinonasal cancers, there is a paucity of data regarding strategy for their optimal treatment. Generally, outcomes of advanced and higher grade tumors remain unsatisfactory, despite the employment of sophisticated surgical approaches, technical advances in radiation techniques and the use of heavy ion particles. In this context, we critically evaluated the role of systemic therapy as part of a multidisciplinary approach to locally advanced disease. Results: Induction chemotherapy has shown encouraging activity and could have a role in the multimodal treatment of patients with advanced sinonasal tumors. For epithelial tumors, the most frequently employed chemotherapy is cisplatin, in combination with either 5-fluorouracil, taxane, ifosfamide, or vincristine. Only limited experiences with concurrent chemoradiation exist with sinonasal cancer. The role of systemic treatment for each histological type (intestinal-type adenocarcinoma, sinonasal undifferentiated carcinoma, sinonasal neuroendocrine carcinoma, olfactory neuroblastoma, sinonasal primary mucosal melanoma, sarcoma) is discussed. Conclusions: The treatment of SNC requires a multimodal approach. Employment of systemic therapy for locally advanced disease could result in better outcomes, and optimize the therapeutic armamentarium. Further studies are needed to precisely define the role of systemic therapy and identify the optimal sequencing for its administration in relation to local therapies.",
author = "Paolo Bossi and Saba, {Nabil F.} and Vermorken, {Jan B.} and Primoz Strojan and Laura Pala and {De Bree}, Remco and Rodrigo, {Juan Pablo} and Fernando Lopez and Hanna, {Ehab Y.} and Missak Haigentz and Takes, {Robert P.} and Slootweg, {Piet J.} and Silver, {Carl E.} and Alessandra Rinaldo and Alfio Ferlito",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ctrv.2015.07.004",
language = "English (US)",
volume = "41",
pages = "836--843",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "10",

}

Bossi, P, Saba, NF, Vermorken, JB, Strojan, P, Pala, L, De Bree, R, Rodrigo, JP, Lopez, F, Hanna, EY, Haigentz, M, Takes, RP, Slootweg, PJ, Silver, CE, Rinaldo, A & Ferlito, A 2015, 'The role of systemic therapy in the management of sinonasal cancer: A critical review', Cancer Treatment Reviews, vol. 41, no. 10, pp. 836-843. https://doi.org/10.1016/j.ctrv.2015.07.004

The role of systemic therapy in the management of sinonasal cancer : A critical review. / Bossi, Paolo; Saba, Nabil F.; Vermorken, Jan B.; Strojan, Primoz; Pala, Laura; De Bree, Remco; Rodrigo, Juan Pablo; Lopez, Fernando; Hanna, Ehab Y.; Haigentz, Missak; Takes, Robert P.; Slootweg, Piet J.; Silver, Carl E.; Rinaldo, Alessandra; Ferlito, Alfio.

In: Cancer Treatment Reviews, Vol. 41, No. 10, 01.01.2015, p. 836-843.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of systemic therapy in the management of sinonasal cancer

T2 - A critical review

AU - Bossi, Paolo

AU - Saba, Nabil F.

AU - Vermorken, Jan B.

AU - Strojan, Primoz

AU - Pala, Laura

AU - De Bree, Remco

AU - Rodrigo, Juan Pablo

AU - Lopez, Fernando

AU - Hanna, Ehab Y.

AU - Haigentz, Missak

AU - Takes, Robert P.

AU - Slootweg, Piet J.

AU - Silver, Carl E.

AU - Rinaldo, Alessandra

AU - Ferlito, Alfio

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: Due to the rarity and the variety of histological types of sinonasal cancers, there is a paucity of data regarding strategy for their optimal treatment. Generally, outcomes of advanced and higher grade tumors remain unsatisfactory, despite the employment of sophisticated surgical approaches, technical advances in radiation techniques and the use of heavy ion particles. In this context, we critically evaluated the role of systemic therapy as part of a multidisciplinary approach to locally advanced disease. Results: Induction chemotherapy has shown encouraging activity and could have a role in the multimodal treatment of patients with advanced sinonasal tumors. For epithelial tumors, the most frequently employed chemotherapy is cisplatin, in combination with either 5-fluorouracil, taxane, ifosfamide, or vincristine. Only limited experiences with concurrent chemoradiation exist with sinonasal cancer. The role of systemic treatment for each histological type (intestinal-type adenocarcinoma, sinonasal undifferentiated carcinoma, sinonasal neuroendocrine carcinoma, olfactory neuroblastoma, sinonasal primary mucosal melanoma, sarcoma) is discussed. Conclusions: The treatment of SNC requires a multimodal approach. Employment of systemic therapy for locally advanced disease could result in better outcomes, and optimize the therapeutic armamentarium. Further studies are needed to precisely define the role of systemic therapy and identify the optimal sequencing for its administration in relation to local therapies.

AB - Purpose: Due to the rarity and the variety of histological types of sinonasal cancers, there is a paucity of data regarding strategy for their optimal treatment. Generally, outcomes of advanced and higher grade tumors remain unsatisfactory, despite the employment of sophisticated surgical approaches, technical advances in radiation techniques and the use of heavy ion particles. In this context, we critically evaluated the role of systemic therapy as part of a multidisciplinary approach to locally advanced disease. Results: Induction chemotherapy has shown encouraging activity and could have a role in the multimodal treatment of patients with advanced sinonasal tumors. For epithelial tumors, the most frequently employed chemotherapy is cisplatin, in combination with either 5-fluorouracil, taxane, ifosfamide, or vincristine. Only limited experiences with concurrent chemoradiation exist with sinonasal cancer. The role of systemic treatment for each histological type (intestinal-type adenocarcinoma, sinonasal undifferentiated carcinoma, sinonasal neuroendocrine carcinoma, olfactory neuroblastoma, sinonasal primary mucosal melanoma, sarcoma) is discussed. Conclusions: The treatment of SNC requires a multimodal approach. Employment of systemic therapy for locally advanced disease could result in better outcomes, and optimize the therapeutic armamentarium. Further studies are needed to precisely define the role of systemic therapy and identify the optimal sequencing for its administration in relation to local therapies.

UR - http://www.scopus.com/inward/record.url?scp=84958921999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958921999&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.07.004

DO - 10.1016/j.ctrv.2015.07.004

M3 - Review article

C2 - 26255226

AN - SCOPUS:84958921999

VL - 41

SP - 836

EP - 843

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 10

ER -